The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

(2022) Willemijn J. Jansen et al.   JAMA Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives

(2021) Matteo Cotta Ramusino et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

(2021) Bruno Dubois et al.   LANCET NEUROLOGY

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

(2021) Elisabeth H Thijssen et al.   LANCET NEUROLOGY

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab

(2021) Gil D. Rabinovici   NEW ENGLAND JOURNAL OF MEDICINE

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

(2021) Hyemin Jang et al.   Alzheimers Research & Therapy

PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape

(2020) Bright Chukwunwike Uzuegbunam et al.   MOLECULES

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer’s Disease

(2020) Roos J. Jutten et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS

(2020) Gil D. Rabinovici et al.   Alzheimers & Dementia

Diagnostic Accuracy of Amyloid versus 18 F‐Fluorodeoxyglucose Positron Emission Tomography in Autopsy‐Confirmed Dementia

(2020) Orit H. Lesman‐Segev et al.   ANNALS OF NEUROLOGY

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

(2018) Ron Brookmeyer et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

(2018) Victor L. Villemagne et al.   Nature Reviews Neurology

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

(2018) David A. Wolk et al.   JAMA Neurology

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort

(2018) Arno de Wilde et al.   JAMA Neurology

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

AMYPAD Diagnostic and Patient Management Study: Rationale and design

(2018) Giovanni B. Frisoni et al.   Alzheimers & Dementia

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Use and Utility of Amyloid Imaging

(2017) Henryk Barthel et al.   JOURNAL OF NUCLEAR MEDICINE

Regional correlations between [ 11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort

(2017) Sang Won Seo et al.   NeuroImage-Clinical

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

(2015) Sylvia Villeneuve et al.   BRAIN

Prevalence of Amyloid PET Positivity in Dementia Syndromes

(2015) Rik Ossenkoppele et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

(2015) Craig Curtis et al.   JAMA Neurology

Amyloid and APOE  4 interact to influence short-term decline in preclinical Alzheimer disease

(2014) E. C. Mormino et al.   NEUROLOGY

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

(2011) G. D. Rabinovici et al.   NEUROLOGY

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cerebral amyloidosis: amyloid subunits, mutants and phenotypes

(2009) A. Rostagno et al.   CELLULAR AND MOLECULAR LIFE SCIENCES